KAS
COGT icon

Kemnay Advisory Services’s Cogent Biosciences COGT Stock Holding History

Kemnay Advisory Services’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49K Buy
1,272
+812
+177% +$30K 0.01% 265
2025
Q4 		$16.3K Buy
+460
New +$12.9K ﹤0.01% 610

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Kemnay Advisory Services's COGT Position: Q1 2026 in Review

Kemnay Advisory Services increased its Cogent Biosciences (COGT) stake by 177% in Q1 2026, buying an estimated $30K and bringing the position to 1,272 shares worth $49K. The position accounts for 0.01% of the portfolio, ranked #265.

Kemnay Advisory Services first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Kemnay Advisory Services held 1,272 shares of Cogent Biosciences worth $49K as of Q1 2026.
  • Kemnay Advisory Services bought 812 Cogent Biosciences shares in Q1 2026, an estimated $30K.
  • Cogent Biosciences made up 0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #265 holding.
  • Kemnay Advisory Services first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.